CatalystFDA/Bio

Iovance sees long-term response for Amtagvi in first-line melanoma

Iovance reports long-term response for Amtagvi in first-line melanoma.

What changed

Iovance reports long-term response for Amtagvi in first-line melanoma.

Why it matters

Iovance reports long-term response for Amtagvi in first-line melanoma. — impact context not separately stored; see What changed.

Sources